Introduction
The Polymyxin International Conference has successfully held 3 offline academic conferences in Prato, Italy, San Diego, USA, and Madrid, Spain respectively from 2013 to 2018. Since our last gathering in Madrid in 2018, the field has seen remarkable advancements. However, there are still a number of major challenges in the clinical use of polymyxins and new drug discovery.
The 2024 Conference will explore all facets of polymyxin use, from clinical practice and one health strategies to pharmacology, drug discovery, regulatory considerations, and strategic initiatives around the globe. This forum will offer an unparalleled opportunity for infectious disease clinicians, pharmacists, microbiologists, pharmacologists and R&D scientists globally to converge, sharing the latest insights in polymyxins.
Topics
- Multidrug resistance
- Clinical use of polymyxins in different types of patients
- Optimized dosing of three different types of polymyxin products (CMS, polymyxin B sulfate, colistin sulfate)
- Different delivery routes of polymyxins (e.g. inhalation, intraventricular/intrathecal)
- Toxicities of polymyxins
- MIC measurement and breakpoints
- Use of polymyxin combinations in patients
- Mechanisms of the activity, resistance and toxicities
- Discovery of new-generation polymyxins
- Funding support for the discovery of new antimicrobial therapeutics
- Young investigator network
Important Dates
Conference date: 8-10 October 2024
Registration date:
Early bird until 15 August 2024
Regular until 16 September 2024
Abstract submission deadline:
30 August 2024
Click here to download the conference agenda and invitation letter.
Chairs
Professor Jian Li is an elected Fellow of the Australian Academy of Science, Australian Academy of Health and Medical Science, and American Academy of Microbiology. Jian is Editor-in-Chief of the International Journal of Antimicrobial Agents. Professor Li heads the Laboratory of Antimicrobial Systems Pharmacology at the Monash Biomedicine Discovery Institute in Melbourne, Australia. Jian has an internationally recognised track record in antimicrobial chemotherapy against Gram-negative pathogens and has developed a novel lipopeptide antibiotic from concept to clinical trials.
Professor Jing Zhang, Chief Pharmacist at Huashan Hospital affiliated to Fudan University, holds Deputy Director of the Institute of Antibiotics, Director of the Key Laboratory of Clinical Pharmacology of Antibiotics under the Health Commission, and Director of the Clinical Pharmacology Center. Additionally, Professor Zhang serves as Vice Chairman in committees of both the Chinese Pharmaceutical Association and the Chinese Pharmacological Society. A recipient of the Shanghai Leading Talents Award, Professor Zhang specializes in clinical and quantitative pharmacology, leading 110 Phase I clinical trials and pharmacokinetic studies since 2019.
Hosted by
Permission to use the logo of the International Society of Antimicrobial Chemotherapy (ISAC) is granted on condition that the ISAC does not thereby undertake any liabilities for the event, or from anything that takes place at or following the event.
Display of the logo does not signify that the ISAC endorses all, or any, of the content of the event where the logo is used.